Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

scientific article

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.3389/FNCEL.2014.00369
P8608Fatcat IDrelease_qtnqc5cecjhi5alpcgplqlriri
P932PMC publication ID4227512
P698PubMed publication ID25426023
P5875ResearchGate publication ID269660400

P50authorHortensia Alonso-NavarroQ90025041
José AgundezQ42720672
Elena García-MartínQ37610485
P2093author name stringFélix J Jiménez-Jiménez
P2860cites workLevels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseasesQ28270925
The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's diseaseQ28325517
Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's diseaseQ69098325
Dipeptidyl-aminopeptidase II in human cerebrospinal fluid: changes in patients with Parkinson's diseaseQ69115997
[Leukotrienes and neurological diseases]Q69158288
Serotonin and 5-hydroxyindoleacetic acid in CSF. Difference in Parkinson's disease and dementia of the Alzheimer's typeQ69381597
Magnitude of response to levodopa in Parkinson disease as it relates to peripheral and central measurements of levodopa and associated metabolitesQ69425315
Alteration of amino acids in cerebrospinal fluid from patients with Parkinson's disease and spinocerebellar degenerationQ69503377
Increase of oxidized/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson's diseaseQ83220912
Biopterin levels in the cerebrospinal fluid of patients with PARK8 (I2020T)Q83360391
CSF markers of neurodegeneration in Parkinson's diseaseQ84786273
Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndromeQ85020419
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjectsQ85425444
Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's diseaseQ88076090
Hydroxylase Cofactor Activity in Cerebrospinal Fluid of Normal Subjects and Patients with Parkinson's DiseaseQ28326297
Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonismQ28336577
Study on the concentration of 5-hydroxyindoleacetic acid (5-HIAA) in the lumbar cerebrospinal fluid (CSF) in neurological diseasesQ28340408
CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosisQ28731571
Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohortQ30405991
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's diseaseQ30493811
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progressionQ30501271
Phosphorylated α-synuclein in Parkinson's diseaseQ30510167
Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease.Q31823176
Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's diseaseQ33525158
Ferritin in the cerebrospinal fluid of patients with Parkinson's diseaseQ33589109
Cerebrospinal fluid arginine vasopressin in degenerative disorders and other neurological diseasesQ33618361
Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementiaQ33622879
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson diseaseQ33666297
N-methyl(R)salsolinol, a dopamine neurotoxin, in Parkinson's disease.Q33689680
Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSFQ33756474
Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosisQ33981403
CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's diseaseQ33994583
Urate as a predictor of the rate of clinical decline in Parkinson diseaseQ34019732
Elevated levels of harman and norharman in cerebrospinal fluid of parkinsonian patientsQ34064156
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson diseaseQ34140382
1‐Benzyl‐1,2,3,4‐Tetrahydroisoquinoline as a Parkinsonism‐Inducing Agent: A Novel Endogenous Amine in Mouse Brain and Parkinsonian CSFQ34298649
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.Q34299993
Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementiaQ34469280
Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathyQ34544824
Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophyQ34805505
Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's diseaseQ34806122
DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic functionQ35757332
Decreased beta-phenylethylamine in CSF in Parkinson's diseaseQ36317491
Differential sialylation of serpin A1 in the early diagnosis of Parkinson's disease dementiaQ36384748
Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's diseaseQ36718213
Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.Q36852905
Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjectsQ36925296
CSF somatostatin-like immunoreactivity in dementia of Parkinson's diseaseQ36943074
Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patientsQ42167232
Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disordersQ42202451
CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.Q42274526
Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvementQ42276279
Presence of N-methyl-norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's diseaseQ42276779
Reduced and oxidized forms of glutathione and alpha-tocopherol in the cerebrospinal fluid of parkinsonian patients: comparison between before and after L-dopa treatmentQ42278983
Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's diseaseQ42287995
The glial marker YKL-40 is decreased in synucleinopathiesQ42441318
Cerebrospinal fluid homovanillic acid levels are not reduced in early corticobasal degenerationQ42455831
Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's diseaseQ42472074
Ventricular somatostatin-like immunoreactivity in patients with basal ganglia diseaseQ42503236
Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleusQ42515011
bcl-2 protein is increased in the brain from parkinsonian patientsQ42526032
(E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's diseaseQ42541023
Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disordersQ42547717
Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's diseaseQ42548051
Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3.Q42904569
Polyamine patterns in the cerebrospinal fluid of patients with Parkinson's disease and multiple system atrophyQ43048638
Ventricular orexin-A (hypocretin-1) levels correlate with rapid-eye-movement sleep without atonia in Parkinson's disease.Q43102395
L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's diseaseQ43113090
Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease.Q43225553
Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodQ43234302
Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depressionQ43257873
beta-Endorphin cerebrospinal fluid decrease in untreated parkinsonian patientsQ43522910
Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's diseaseQ43538416
Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolismQ43547469
Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease.Q43792598
Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's diseaseQ43841073
CSF monoamine metabolite levels in Alzheimer's and Parkinson's diseaseQ43844328
Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophyQ43918307
Ventricular fluid neuropeptides in Parkinson's disease. I. Levels and distribution of somatostatin-like immunoreactivityQ44005163
Increased neopterin production and tryptophan degradation in advanced Parkinson's diseaseQ44035901
Post-proline cleaving enzyme in human cerebrospinal fluid from control patients and parkinsonian patientsQ44101763
Presence of methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines, derivatives of the neurotoxin isoquinoline, in parkinsonian lumbar CSF.Q44138760
Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's diseaseQ44260283
Opioid peptides in Parkinson's disease: effects of dopamine repletionQ44335345
Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's diseaseQ44496527
Concentrations of 5-Hydroxyindole-acetic Acid and Homovanillic Acid in the Cerebrospinal Fluid after Treatment with Probenecid in Patients with Parkinson's DiseaseQ44496744
Cerebrospinal fluid and plasma clusterin levels in Parkinson's diseaseQ44530761
Concentrations of neopterin and biopterin in the cerebrospinal fluid of patients with Parkinson's diseaseQ44610902
Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease.Q44642324
Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type.Q44745912
Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medicationQ44748626
Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease.Q45152977
Clinical and biochemical features of depression in Parkinson's diseaseQ45195312
Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases.Q45288825
Cerebrospinal fluid levels of diazepam-binding inhibitor in neurodegenerative disorders with dementiaQ45294244
CSF somatostatin-like immunoreactivity in dementiaQ45296600
Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's choreaQ45299155
Homovanillic acid in the cerebrospinal fluid: studies in Parkinson's syndrome and other diseases of the CNSQ45301340
Adenosine 3',5'-monophosphate in cerebrospinal fluid. Effect of drugs and neurologic diseaseQ45303235
Analysis of neurotransmitter metabolites and adenosine 3',5'-monophosphate in the CSF of patients with extrapyramidal motor disordersQ45304050
Gamma-aminobutyric acid (GABA) in cerebrospinal fluidQ45304767
Parkinson's disease and benign essential tremor: somatostatin-like immunoreactivity in the cerebrospinal fluidQ45305074
Free and conjugated GABA in human cerebrospinal fluid: Effect of degenerative neurologic diseases and isoniazidQ45305366
Levels of gamma-aminobutyric acid in cerebrospinal fluid in various neurologic disordersQ45306051
Oligoclonal IgG bands in cerebrospinal fluid in various neurological diseasesQ45306983
CSF biomarkers in different phenotypes of Parkinson diseaseQ45753674
Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's diseaseQ46189772
High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients.Q46456086
Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's diseaseQ46527170
Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's diseaseQ46802886
Cerebrospinal-fluid tau protein and aspartate aminotransferase in Parkinson's diseaseQ47860357
Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disordersQ47996302
Cerebrospinal fluid levels of thiamine in patients with Parkinson's diseaseQ48122219
Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's diseaseQ48134664
Neurotrophins and cytokines in Parkinson's disease.Q48160124
Hypocretin (orexin) loss in Parkinson's diseaseQ48182911
Acetyl- and butyrylcholinesterase activity in the cerebrospinal fluid of patients with Parkinson's diseaseQ48184947
Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patientsQ48191627
Impact of selenium, iron, copper and zinc in on/off Parkinson's patients on L-dopa therapyQ48194683
CFS hydroxylase cofactor levels in some neurological diseasesQ37000762
CSF and plasma GABA levels in Parkinson's diseaseQ37019862
Cerebrospinal fluid GABA levels in various neurological and psychiatric diseasesQ37019894
CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disordersQ37057057
The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopaQ37067896
Cerebrospinal fluid choline in extrapyramidal disordersQ37086864
Interactions of L-dopa and amantadine in patients with ParkinsonismQ37090984
An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapyQ37091013
Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophyQ37114685
May the evaluation of nitrosative stress through selective increase of 3-nitrotyrosine proteins other than nitroalbumin and dominant tyrosine-125/136 nitrosylation of serum α-synuclein serve for diagnosis of sporadic Parkinson's disease?Q37147697
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseasesQ37208032
Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson diseaseQ37228718
The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's diseaseQ37736608
CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controlsQ38145962
Genomic and pharmacogenomic biomarkers of Parkinson's disease.Q38201524
Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal studyQ38452068
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's DiseaseQ38641189
Acetylcholine and choline in cerebrospinal fluid of patients with Parkinson's disease and Huntington's choreaQ39301729
Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's diseaseQ39376713
Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's diseaseQ39411963
Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathiesQ39549489
Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disordersQ39577317
Brain dopamine turnover and the relief of parkinsonismQ39581042
The activity of aminotransferases in serum and cerebrospinal fluid in neurological diseases (author's transl)Q39761014
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort studyQ39783457
Cerebrospinal Fluid -Aminobutyric Acid Variations in Neurological DisordersQ39830791
Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonismQ40060520
The effect of L-dopa and propranolol on human CSF cyclic nucleotidesQ40167962
Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's diseaseQ40278884
Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's diseaseQ40441648
A case control study of CSF copper, iron and manganese in Parkinson diseaseQ41126815
Levels of pros-methylimidazoleacetic acid: correlation with severity of Parkinson's disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated miceQ41164734
The relationship of serotonin to depression in Parkinson's diseaseQ41254642
A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's diseaseQ41613762
The role of nitric oxide in neurodegeneration. Potential for pharmacological interventionQ41757009
Histamine Metabolites and pros-Methylimidazoleacetic Acid in Human Cerebrospinal FluidQ41981306
Decreased ferritin levels in brain in Parkinson's diseaseQ42000755
Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's diseaseQ42045096
Complement protein isoforms in CSF as possible biomarkers for neurodegenerative diseaseQ42144037
CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.Q51050295
Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSFQ51107926
Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease.Q51112716
Cerebrospinal fluid levels of 3-methoxy4hydroxyphenylethylene glycol in Parkinsonism before and after treatment with L-DOPAQ51121463
Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonismQ51160311
5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome.Q51211033
On the Occurrence of Homovanillic Acid and 5-Hydroxyindol-3-ylacetic Acid in the Ventricular C.S.F. of Patients Suffering from ParkinsonismQ51222870
Relationship of age and mood to monoamine metabolites in cerebrospinal fluid in parkinsonism.Q51307459
Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous systemQ51677472
Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.Q51892103
CSF somatostatin increase in patients with early parkinsonian syndrome.Q52019874
Parkinson's disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood.Q52056878
Clinical and biochemical correlates of bradyphrenia in Parkinson's disease.Q52074381
Amino acid abnormalities in cerebrospinal fluid and blood serum of patients with Parkinson's disease, other heredodegenerative disorders and head injuries.Q52548941
Parkinson's disease and dementia: clinical and neurochemical correlationsQ53179312
beta-Endorphin-like immunoreactivity in cerebrospinal fluid of patients with Alzheimer's disease and Parkinson's disease.Q53190554
Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy.Q53201956
[Simultaneous determination of catecholamines, serotonin, and their precursors and metabolites in body fluid by an HPLC system with multi-electrode electrochemical detector]Q53204387
Concentration of neural thread protein in cerebrospinal fluid from progressive supranuclear palsy and Parkinson's disease.Q53208366
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?Q53212854
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.Q53213249
Determination of acetylcholine concentration in cerebrospinal fluid of patients with neurologic diseases.Q53213589
Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.Q53246758
Pattern of Tau forms in CSF is altered in progressive supranuclear palsy.Q53288614
Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controlsQ53292491
Differential distribution of neuregulin in human brain and spinal fluid.Q53299220
Immunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients.Q53299881
[Acetylcholinesterase activity in CSF in senile dementia of Alzheimer type, vascular dementia, and Parkinson's disease]Q53301778
Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.Q53303462
Monoamine metabolites in human cerebrospinal fluid. HPLC/ED methodQ53308312
Patterns of levels of biological metals in CSF differ among neurodegenerative diseases.Q53316529
Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy.Q53337561
High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β-amyloid in Parkinson disease.Q53417457
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease.Q53417610
Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patients.Q54359584
Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes.Q54587226
Cerebrospinal fluid corticotropin-releasing hormone in neurodegenerative diseases: reduction in spinocerebellar degeneration.Q55063207
Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementiasQ57750814
Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease DementiaQ58478217
Changes in the concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson's diseaseQ58852569
Tetrahydrobiopterin and Parkinson's diseaseQ59549029
Fe and Cu do not differ in Parkinson's disease: A replication study plus meta-analysisQ60609983
CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disordersQ63456912
Methionine enkephalin, substance P, and homovanillic acid in the CSF of parkinsonian patientsQ64761525
CSF GABA levels in Parkinson's diseaseQ64762967
Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disordersQ64763395
L-glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patientsQ64781321
Low CSF GABA in parkinsonian patients who respond poorly to therapy or suffer from the “on-off” phenomenonQ64781386
Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseasesQ64786329
[Comparison between the effects of L-dopa, prodipine and amantadine on the serum and CSF amino acid levels in Parkinson's disease (author's transl)]Q64787929
Aging and CSF hydroxylase cofactorQ64789931
Decreased concentration of annexin V in parkinsonian cerebrospinal fluid: speculation on the underlying causeQ64819957
Oxidative stress indicators are elevated in de novo Parkinson's disease patients.Q64821241
R- and S-salsolinol are not increased in cerebrospinal fluid of Parkinsonian patientsQ64859998
Cerebrospinal fluid selenium and chromium levels in patients with Parkinson's diseaseQ64866262
Oxidative stress and Parkinson's diseaseQ64866398
No increase of synthesis of (R)salsolinol in Parkinson's diseaseQ48198915
Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsyQ48202209
Low levels of ventricular CSF orexin/hypocretin in advanced PD.Q48217719
Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's diseaseQ48218181
Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness?Q48235911
Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseasesQ48260033
An endogenous MPTP-like dopaminergic neurotoxin, N-methyl(R)salsolinol, in the cerebrospinal fluid decreases with progression of Parkinson's diseaseQ48264694
Low level of ventricular CSF orexin-A is not associated with objective sleepiness in PD.Q48279820
Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's diseaseQ48289983
Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP modelQ48327855
Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementiaQ48384242
The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's diseaseQ48385118
The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controlsQ48386016
Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's diseaseQ48391021
Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patientsQ48394245
Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's diseaseQ48402580
CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degenerationQ48411834
Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's diseaseQ48438362
The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).Q48486699
Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsyQ48509725
Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patientsQ48545459
Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disordersQ48560437
Lack of changes in ventricular cerebrospinal fluid concentrations of homovanillic acid following acute challenge with levodopaQ48569190
Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD.Q48605519
Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodologyQ48629923
Altered serotonin metabolism in depressed patients with parkinson's diseaseQ48680548
Total biopterin levels in the ventricular CSF of patients with Parkinson's disease: a comparison between akineto-rigid and tremor typesQ48713953
The concentration of homovanillic and 5-hydroxyindoleacetic acids in ventricular and lumbar CSF. Studies in patients with extrapyramidal disorders, epilepsy, and other diseasesQ48719108
A significant reduction of putative transmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease and spinocerebellar degenerationQ48719963
Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?Q48819771
Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's diseaseQ48822750
TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluidQ48856015
Tau forms in CSF as a reliable biomarker for progressive supranuclear palsyQ48858527
Concentration of homovanillic acid in the ventricular fluid of patients with Parkinson's disease and other dyskinesiasQ48893374
Cerebrospinal fluid choline levels are decreased in Parkinson's diseaseQ48956570
Comparison of DSIP- (delta sleep-inducing peptide) and P-DSIP-like (phosphorylated) immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type, multi-infarct syndrome, communicating hydrocephalus and Parkinson's diseaQ48972190
Measurement of lumbar CSF levels of met-enkephalin, encrypted met-enkephalin, and neuropeptide Y in normal patients and in patients with Parkinson's disease before and after autologous transplantation of adrenal medulla into the caudate nucleusQ49074131
Cerebrospinal fluid nitrate levels in patients with Parkinson's diseaseQ49136063
Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease.Q50262786
Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.Q50596072
Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.Q50637977
Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies.Q50664328
Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity.Q50711777
3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis.Q50732857
Cerebrospinal fluid cyclic guanosine 3'5' monophosphate levels in Parkinson's disease.Q50893237
Superoxide dismutase activity in cerebrospinal fluid of patients with dementia and some other neurological disorders.Q50896980
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.Q50940972
The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia.Q51027167
???Q64767716
???Q64777647
???Q64779261
???Q64781356
???Q64785254
???Q64864260
???Q64878393
???Q64878762
???Q64878784
???Q64891570
???Q64891572
???Q64891583
???Q64900619
???Q64937450
???Q64966069
Cerebrospinal fluid levels of transition metals in patients with Parkinson's diseaseQ64870117
Free amino acids in the cerebrospinal fluid in old age and in Parkinson's diseaseQ64871767
[Salsolinol, 3-O-methyl-dopa and homovanillic acid in the cerebrospinal fluid of Parkinson patients]Q64917941
Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's diseaseQ64922770
5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L-DOPAQ64942454
Central levodopa metabolism in Parkinson's disease after administration of stable isotope-labeled levodopa.Q64961710
Serial determinations of homovanillinic acid in the cerebrospinal fluid of Parkinson patients treated with L-dopa.Q67207400
Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.Q67207616
L-dopa and cerebrospinal fluid homovanillic acid in parkinsonismQ67213491
Cerebrospinal fluid carnitine levels in patients with Parkinson's diseaseQ67215709
Cerebrospinal fluid acetylcholine in manQ67217929
Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson's diseaseQ67218084
Concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism compared to Parkinson's disease patientsQ67218923
Glutamic oxaloacetic transaminase in serum and cerebrospinal fluid in parkinsonism.Q67223416
Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's diseaseQ67225171
Humoral response to hsp 65 and hsp 70 in cerebrospinal fluid in Parkinson's diseaseQ67237611
A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in parkinsonian cerebrospinal fluidQ67243091
Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease.Q67243561
Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapyQ67653142
Ventricular fluid neuropeptides in Parkinson's disease. II. Levels of substance P-like immunoreactivityQ67687425
Neurokinin concentrations in cerebrospinal fluid. A preliminary study in Parkinson's diseaseQ67853306
Concentrations of tyrosine, L-dihydroxyphenylalanine, dopamine, and 3-O-methyldopa in the cerebrospinal fluid of Parkinson's diseaseQ67996540
Diazepam binding inhibitor-like immunoreactivity (DBI-LI) in human CSF. Correlations with neurological disordersQ68002734
Juvenile parkinsonism: ventricular CSF biopterin levels and clinical featuresQ68034459
Cerebrospinal fluid amino compounds in Parkinson's disease. Alterations due to carbidopa/levodopaQ68254813
Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patientsQ68633495
[Drug-induced dyskinesia during the treatment of Parkinson disease--biochemical studies]Q68958851
Depression and Parkinson's disease: possible role of serotonergic mechanismsQ68988930
Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluidQ69095363
Beta 2-microglobulin decrease in cerebrospinal fluid from parkinsonian patientsQ69551845
[The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment]Q69748784
Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's diseaseQ69749335
Cerebrospinal fluid arginine vasopressin in Parkinson's disease, dementia, and other degenerative disordersQ69771890
Alpha-melanocyte-stimulating hormonelike immunoreactivity is increased in cerebrospinal fluid of patients with Parkinson's diseaseQ69842781
CSF cyclic nucleotides and somatostatin in Parkinson's diseaseQ69875138
Reduced cholecystokinin levels in cerebrospinal fluid of parkinsonian and schizophrenic patients. Effect of ceruletide in schizophreniaQ69903255
Raised cerebrospinal-fluid copper concentration in Parkinson's diseaseQ69903302
CSF dopamine-beta-hydroxylase activity in Parkinson's diseaseQ70077514
Cyclic nucleotides in cerebrospinal fluid of drug-free Parkinson patientsQ70191540
Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's diseaseQ70285006
The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patientsQ70575719
Vasoactive intestinal peptide in cerebrospinal fluidQ70598937
Cerebrospinal fluid choline levels in Parkinson's diseaseQ70777485
Increased cerebrospinal fluid concentration of nitrite in Parkinson's diseaseQ70802059
Nitrite, nitrate and cGMP in the cerebrospinal fluid in degenerative neurologic diseasesQ71370105
Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's diseaseQ71525806
Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-DopaQ71542503
Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administrationQ71603417
beta-Carbolinium cations, endogenous MPP+ analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's diseaseQ71631171
CSF acetylcholinesterase in Parkinson disease: decreased enzyme activity and immunoreactivity in demented patientsQ71956055
Concentrations of serotonin and its related substances in the cerebrospinal fluid of Parkinsonian patients and their relations to the severity of symptomsQ72076551
Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson's diseaseQ72129356
Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+Q72142393
[Trace elements analysis of serum and cerebrospinal fluid with PIXE--effect of age and changes in parkinsonian patients]Q72171643
gamma delta+ T cells are increased in patients with Parkinson's diseaseQ72304394
Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patientsQ72304398
[The effect of droxidopa on the monoamine metabolsim in the human brain]Q72456444
Depression in Parkinson's disease: biogenic amines in CSF of "de novo" patientsQ73065148
Normal cerebrospinal fluid levels of insulin in patients with Parkinson's diseaseQ73533437
Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's diseaseQ74624169
Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's diseaseQ74624173
Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsyQ78828029
Nitrite and malondialdehyde content in cerebrospinal fluid of patients with Parkinson's diseaseQ79404888
Polyunsaturated fatty acid levels in the cerebrospinal fluid of patients with Parkinson's disease and multiple system atrophyQ80165349
Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's diseaseQ80342694
Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's diseaseQ80424021
Elemental profile of cerebrospinal fluid in patients with Parkinson's diseaseQ81547777
Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer diseaseQ82257191
CSF α-synuclein does not differentiate between parkinsonian disordersQ83209287
P921main subjectbiomarkerQ864574
Parkinson's diseaseQ11085
cerebrospinal fluidQ54196
P304page(s)369
P577publication date2014-11-11
P1433published inFrontiers in Cellular NeuroscienceQ2131509
P1476titleCerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease
P478volume8

Reverse relations

cites work (P2860)
Q92055253Association of LAG3 genetic variation with an increased risk of PD in Chinese female population
Q58805374Bioelemental patterns in the cerebrospinal fluid as potential biomarkers for neurodegenerative disorders
Q41666702Biomarker Research in Parkinson's Disease Using Metabolite Profiling
Q49942492Biomarkers for Parkinson's Disease: Recent Advancement.
Q40460924Brain-derived neurotrophic factor serum levels correlate with cognitive performance in Parkinson's disease patients with mild cognitive impairment.
Q53512696Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis.
Q41974638Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy
Q94544384Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid
Q41829630Editorial on Cerebral endothelial and glial cells are more than bricks in the Great Wall of the brain: insights into the way the blood-brain barrier actually works (celebrating the centenary of Goldman's experiments).
Q58084961Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinson's disease diagnosis
Q60949823Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease
Q64228408Inflammation, Infectious Triggers, and Parkinson's Disease
Q60304733Metabolomic investigations in cerebrospinal fluid of Parkinson's disease
Q42380034Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Q58572579Recent Advances in Biomarkers for Parkinson's Disease
Q26738420Somatostatin and Somatostatin-Containing Neurons in Shaping Neuronal Activity and Plasticity
Q35783515Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease
Q47712262Timed Release of Cerebrolysin Using Drug-Loaded Titanate Nanospheres Reduces Brain Pathology and Improves Behavioral Functions in Parkinson's Disease.
Q92017939What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations?

Search more.